- Home
- Companies
- Celularity Inc.
- Products
- Celularity - Postpartum Placenta
Celularity - Postpartum Placenta
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum placenta.
One of the biggest challenges cell therapy developers face is the human immune system—how do you make a cell-based treatment that the patient’s immune system does not reject as foreign?
Currently approved treatments overcome this challenge by using the patient’s own cells, autologous cell therapy, an approach that is extremely expensive and difficult to scale.
At Celularity, we start with a material that normally possess a low potential for provoking an immune response, the placenta, to develop allogeneic cell therapies that can be used without the need for matching the patient to the donor.
Then, using our proprietary technology, we convert a plentiful and normally discarded source material into potential therapeutics, with a single placenta capable of yielding 100 – 100,000+ doses, depending on the therapeutic.
Our technology makes it possible to develop cell therapies that are scalable and cost-effective, and that can accelerate preclinical development to as little as 18 – 24 months.